Baylor Scott & White, Memorial Hermann won’t merge

After signing a letter of intent to explore a merger in October 2018, Baylor Scott & White Health and Memorial Hermann Health System have dissolved the plan.

“After months of thoughtful exploration, we have decided to discontinue talks of a merger between our two systems. Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time,” read a joint statement issued Feb. 5.

Under a merger, the two not-for-profit, Texas-based health systems would have created a large entity representing about 15 percent of the state’s hospitals. The combined system would have included 68 hospitals and more than 1,100 care delivery sites.

The two organizations did not state a specific reason for the breakup. However, future collaborations between the two health systems are still a possibility.

“We have a tremendous amount of respect for each other and remain committed to strengthening our communities, advancing the health of Texans and transforming the delivery of care,” the statement concluded. “We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.